ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · IEX Real-Time Price · USD
18.77
-0.43 (-2.24%)
At close: Jul 19, 2024, 4:30 PM
19.08
+0.31 (1.65%)
Pre-market: Jul 22, 2024, 7:36 AM EDT
ArriVent BioPharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 29.25, with a low estimate of 25 and a high estimate of 35. The average target predicts an increase of 55.83% from the current stock price of 18.77.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 6, 2024.
Analyst Ratings
The average analyst rating for AVBP stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +33.19% | Jun 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +33.19% | May 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +33.19% | Apr 30, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +59.83% | Feb 20, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +86.47% | Feb 20, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.23
from -32.38
EPS Next Year
-2.95
from -3.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 17.9M | 147.0M | 350.7M |
| Avg | n/a | n/a | 9.1M | 102.6M | 232.1M |
| Low | n/a | n/a | n/a | 60.0M | 118.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,519.3% | 241.8% |
| Avg | - | - | - | 1,030.3% | 126.2% |
| Low | - | - | - | 560.7% | 15.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.51 | -2.18 | -2.34 |
| Avg | -3.23 | -2.95 | -3.06 |
| Low | -4.12 | -4.14 | -4.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.